Patents Examined by Claire M. Kaufman
  • Patent number: 7148026
    Abstract: The present invention features polypeptides and nucleic acids related to a dog MCH receptor and uses of such polypeptides and nucleic acids. The dog MCH receptor is a G protein coupled receptor whose activity is stimulated by MCH binding.
    Type: Grant
    Filed: July 17, 2001
    Date of Patent: December 12, 2006
    Assignee: Merck & Co., Inc.
    Inventor: Carina Tan
  • Patent number: 7118890
    Abstract: The present invention relates to nucleotide sequences of vertebrate Delta genes, and amino acid sequences of their encoded proteins, as well as derivatives (e.g., fragments) and analogs thereof. In a specific embodiment, the vertebrate Delta protein is a human protein. The invention further relates to fragments (and derivatives and analogs thereof) of Delta which comprise one or more domains of the Delta protein, including but not limited to the intracellular domain, extracellular domain, DSL domain, domain amino-terminal to the DSL domain, transmembrane region, or one or more EGF-like repeats of a Delta protein, or any combination of the foregoing. Antibodies to Delta, its derivatives and analogs, are additionally provided. Methods of production of the Delta proteins, derivatives and analogs, e.g., by recombinant means, are also provided. Therapeutic and diagnostic methods and pharmaceutical compositions are provided.
    Type: Grant
    Filed: February 15, 2001
    Date of Patent: October 10, 2006
    Assignees: Yale University, Imperial Cancer Research Technology, Ltd.
    Inventors: David Ish-Horowicz, Domingos Manuel Pinto Henrique, Julian Hart Lewis, Spyridon Artavanis-Tsakonas, Grace E. Gray
  • Patent number: 7115394
    Abstract: The present invention concerns the discovery of a new family of hedgehog binding proteins, refered to herein as “hedgehog interacting proteins” or “HIPs”, which are demonstrated to bind to hedgehog polypeptides with high affinity. As described herein, the vertebrate HIP proteins exhibit spatially and temporally restricted expression domains indicative of important roles in hedgehog-mediated induction.
    Type: Grant
    Filed: November 4, 2002
    Date of Patent: October 3, 2006
    Assignee: President and Fellows of Harvard College
    Inventors: Andrew P. McMahon, Pao-Tien Chuang
  • Patent number: 7115393
    Abstract: The present invention relates to all facets of novel polynucleotides for melanocortin-1 receptors, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are useful in variety of ways, including, but not limited to, as molecular markers, as drug targets, and for detecting, diagnosing, staging, monitoring, prognosticating, preventing or treating, determining predisposition to, etc., diseases and conditions especially relating to melanocortin-1, such as melanoma, pigmentation disorders and conditions, inflammation, etc.
    Type: Grant
    Filed: June 10, 2002
    Date of Patent: October 3, 2006
    Assignee: OriGene Technologies, Inc.
    Inventors: Youmin Shu, Xuan Li, Anthony C. Yee, Gilbert Jay
  • Patent number: 7115717
    Abstract: Anti-TRAIL-R1 and R2 antibodies or functional fragments thereof, having at least one property selected from the following (a) to (c) of: (a) having activity to induce apoptosis in carcinoma cells expressing TRAIL-R1 and/or TRAIL-R2; (b) not having effect on normal human cells expressing TRAIL-R1 and/or TRAIL-R2; and (c) not inducing human hepatocyte toxicity.
    Type: Grant
    Filed: May 17, 2002
    Date of Patent: October 3, 2006
    Assignee: Kirin Beer Kabushiki Kaisha
    Inventors: Eiji Mori, Shiro Kataoka
  • Patent number: 7098026
    Abstract: Disclosed are a novel hedgehog protein, i.e., a Desert hedgehog protein of human origin including mature and precursor forms, a DNA encoding the protein, a monoclonal antibody recognizing the protein, a process for producing the protein, and a method for detecting the protein. The hedgehog protein is useful in establishment of hybridomas which produce antibodies recognizing the protein, and the monoclonal antibody is useful in detection and purification of the protein. The hedgehog protein, DNA, and monoclonal antibody of this invention have efficacy in elucidation of hereditary morphological abnormalities in humans to establish their treatments and diagnoses.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: August 29, 2006
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Toshio Ariyasu, Shuji Nakamura, Kunzo Orita
  • Patent number: 7094554
    Abstract: A cDNA encoding a 200 kD receptor, BT-R2, from the pink boll worm, Pectinophora gossypiella, that binds specifically to a Bacillus thuringiensis toxin has been cloned, sequenced and characterized. The minimum toxin binding fragment has been identified. The BT-R2 cDNA permits the analysis of receptors in pink boll worm and other insects that affect crop growth and development, as well as, design assays for the cytotoxicity and binding affinity of potential pesticides. The clone and other methods described herein, permit the manipulation of natural and/or introduced homologous receptors and, thus, to specifically destroy organisms, tissues and/or cells of the target host.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: August 22, 2006
    Assignee: The Board of Regents, The University of Texas System
    Inventors: Lee A. Bulla, Mehmet Candas
  • Patent number: 7087390
    Abstract: CAIP polypeptide, nucleic acids, ands uses thereof.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 8, 2006
    Assignee: Biogen Idec MA Inc.
    Inventor: Yen-Ming Hsu
  • Patent number: 7078514
    Abstract: The present invention relates to chicken growth hormone releasing hormone (GHRH), its corresponding receptor, and nucleic acid sequences encoding these proteins. More particularly the present invention is directed to the use of the chicken GHRH hormone and its corresponding GHRH receptor to enhance the production of larger, leaner chickens and other avian species used for meat production.
    Type: Grant
    Filed: June 12, 2000
    Date of Patent: July 18, 2006
    Inventors: Michael O. Thorner, Bruce David Gaylinn, Andrew Alan Toogood, Steve Harvey
  • Patent number: 7071161
    Abstract: The present invention identifies four new isoforms of human corticotropin releasing hormone receptor type 1 (CRH-R1e, 1f, 1g and 1h) and three new isoforms of mouse corticotropin releasing hormone receptor type 1 (mCRH-R1c, 1e and 1f). The data indicate that polymorphism of CRH-R1 expression is related to anatomic location, skin physiological or pathologic status, specific cell type, external stress (UV), and that cAMP dependent pathways and TPA may regulate CRH-R1.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: July 4, 2006
    Assignee: The University of Tennessee Research Corporation
    Inventors: Alexander Pisarchik, Andrzej Slominski
  • Patent number: 7052695
    Abstract: The invention generally relates to angiogenic factors and more particularly to the angiopoietin family of growth factors and to methods of using these growth factors to induce vasodilation and hypotension and reducing hypertension.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: May 30, 2006
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventor: Susan Croll Kalish
  • Patent number: 7015308
    Abstract: Disclosed are a novel hedgehog protein, i.e., a Desert hedgehog protein of human origin including mature and precursor forms, a DNA encoding the protein, a monoclonal antibody recognizing the protein, a process for producing the protein, and a method for detecting the protein. The hedgehog protein is useful in establishment of hybridomas which produce antibodies recognizing the protein, and the monoclonal antibody is useful in detection and purification of the protein. The hedgehog protein, DNA, and monoclonal antibody of this invention have efficacy in elucidation of hereditary morphological abnormalities in humans to establish their treatments and diagnoses.
    Type: Grant
    Filed: April 22, 1998
    Date of Patent: March 21, 2006
    Assignee: Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
    Inventors: Toshio Ariyasu, Shuji Nakamura, Kunzo Orita
  • Patent number: 7005505
    Abstract: The present invention involves the preparation of vascular endothelial growth actor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: February 28, 2006
    Assignee: Genentech, Inc.
    Inventors: Bruce A. Keyt, Francis Hung Nguyen, Napoleone Ferrara
  • Patent number: 6962811
    Abstract: The invention provides isolated nucleic acids molecules, designated 14715 nucleic acid molecules, which encode novel fringe family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing 14715 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a 14715 gene has been introduced or disrupted. The invention still further provides isolated 14715 proteins, fusion proteins, antigenic peptides and anti-14715 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
    Type: Grant
    Filed: May 8, 2002
    Date of Patent: November 8, 2005
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Rosana Kapeller-Libermann, Karen L. Anderson
  • Patent number: 6943020
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity.
    Type: Grant
    Filed: August 23, 2002
    Date of Patent: September 13, 2005
    Assignees: Human Genome Sciences, Inc., The Regents of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Patent number: 6906179
    Abstract: The invention provides novel compositions comprising a Smad protein and an isolated protein component of the proteasome-mediated degradation pathway. The invention also provides novel compositions comprising a Smad1 protein and a substrate for proteasome-mediated degradation. The invention also provides methods of screening for compounds that modulate the interaction between the proteins comprising these compositions. The invention also provides methods of screening for compounds that modulate the activity of the proteins comprising these compositions. The invention also provides methods of detecting proteasome-mediated degradation of novel Smad interacting proteins. A further aspect of the invention is a kit for detecting proteasome-mediated degradation of novel Smad interacting proteins. The invention also provides methods of treating diseases which are associated with aberrant levels of activity of a TGF-? superfamily member.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: June 14, 2005
    Assignee: The General Hospital Corporation
    Inventor: Tongwen Wang
  • Patent number: 6902910
    Abstract: The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides.
    Type: Grant
    Filed: June 21, 2002
    Date of Patent: June 7, 2005
    Assignees: Human Genome Sciences, Inc., The Regent of the University of Michigan
    Inventors: Jian Ni, Craig A. Rosen, James G. Pan, Reiner L. Gentz, Vishva M. Dixit
  • Patent number: 6884775
    Abstract: The present application is directed to the discovery that hedgehog proteins, and agents which effect the activities thereof, can be used to control the formation and/or maintenance of cartilage and bone.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: April 26, 2005
    Assignees: President and Fellows of Harvard College, Imperial Cancer Research Technology, Inc.
    Inventors: Clifford J. Tabin, Andrew P. McMahon, Philip W. Ingham, Andrea M. Vortkamp
  • Patent number: 6881395
    Abstract: The present invention provides for an isolated nucleic acid molecule encoding a member of the TIE ligand family. The present invention also provides for an isolated nucleic acid molecule encoding TIE ligand-3 or TIE ligand-4. In addition, the invention provides for a receptorbody which specifically binds TIE ligand-3 or TIE ligand-4. The invention also provides an antibody which specifically binds TIE ligand-3 or TIE ligand-4. The invention further provides for an antagonist of TIE. The invention also provides for therapeutic compositions as well as a method of blocking blood vessel growth, a method of promoting neovascularization, a method of promoting the growth or differentiation of a cell expressing the TIE receptor, a method of blocking the growth or differentiation of a cell expressing the TIE receptor and a method of attenuating or preventing tumor growth in a human.
    Type: Grant
    Filed: August 8, 2002
    Date of Patent: April 19, 2005
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: David M. Valenzuela, Pamela F. Jones, George D. Yancopoulos
  • Patent number: 6872568
    Abstract: The present invention relates to novel Death Domain Containing Receptor-5 (DR5) proteins which are members of the tumor necrosis factor (TNF) receptor family, and have now been shown to bind TRAIL. In particular, isolated nucleic acid molecules are provided encoding the human DR5 proteins. DR5 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying antagonists and antagonists of DR5 activity.
    Type: Grant
    Filed: May 4, 2000
    Date of Patent: March 29, 2005
    Assignee: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Reiner L. Gentz, Guo-Liang Yu, Craig A. Rosen